Search

Your search keyword '"Poch, Michael"' showing total 547 results

Search Constraints

Start Over You searched for: Author "Poch, Michael" Remove constraint Author: "Poch, Michael"
547 results on '"Poch, Michael"'

Search Results

1. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial

3. A Single Institution Experience in the Management of Localized Neuroendocrine Carcinoma of the Bladder

8. MP71-13 DELAYS IN INITIATING FIRST LINE BLADDER SPARING THERAPY PORTEND WORSE PROGRESSION-FREE SURVIVAL FOR BCG UNRESPONSIVE PATIENTS

10. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.

14. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis

16. DISEASE PROGRESSION IN BCG UNRESPONSIVE PATIENTS: STRATIFICATION OF CIS CONTAINING TUMORS

17. IDENTIFYING THE DRIVER HISTOLOGY RESPONSIBLE FOR THE INFERIOR CLINICOPATHOLOGIC FEATURES ASSOCIATED WITH PLASMACYTOID BLADDER CANCER

18. PREOPERATIVE RADICAL CYSTECTOMY ERAS SCREENING AND EDUCATION – PATIENT REPORTED OUTCOMES

21. Oncolytic Virotherapy Combined with Nivolumab Elicits Complete Responses in Muscle-Invasive Bladder Cancer in Association with the Formation of Tertiary Lymphoid Structures

22. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.

27. Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer

28. Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder

29. Data from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder

30. Table S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder

39. A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder

46. NEXT: A phase 2 study of nivolumab adjuvant to chemoradiation in patients (pts) with localized urothelial carcinoma.

47. Abstract CT157: Combination of nivolumab with standard of care in the management of grade group 5 prostate cancer: Interim analysis of a phase II trial

48. PD44-09 IMPACT OF HIGH-RISK FEATURES AND STAGING ON NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS TREATED WITH RADICAL CYSTECTOMY: A SINGLE CENTER ANALYSIS OF 1700 CASES

49. PD09-09 SURVIVAL BENEFITS OF ADJUVANT CHEMOTHERAPY FOR POSITIVE SOFT TISSUE SURGICAL MARGINS FOLLOWING RADICAL CYSTECTOMY IN BLADDER CANCER WITH EXTRAVESICAL EXTENSION

Catalog

Books, media, physical & digital resources